Johnson & Johnson , Mylan propose ways to cut TB drugs prices in India

Johnson & Johnson and Mylan have proposed measures expected to make their multi-drug resistant tuberculosis medicines available in India at lower rates to ensure patients continue to get access to them after free supplies to the country are stopped, people familiar with the matter said.

15

Read More

An urgent prescription

India is rightly acclaimed to be the pharmacy of the world, with its huge private sector capacity for producing branded and unbranded generic drugs. Much of this growth took place after India opted for process patenting over product patenting in 1970.

Read More

‘India’s IPR policy will drive a new focus on empowering domestic innovators’

Issues like curbs on patent eligibility, compulsory licensing need to be addressed: Global Innovation Policy Centre’s V-P

Read More

Make pharmaceutical patents work in the public interest

A Delhi High Court case shines a light on why public disclosure on working a patent is critical for compulsory licensing and public health

Read More